Moderna Inc said on Thursday its Covid-19 vaccine was about 93% effective through six months after the second dose, showing hardly any change from the 94% efficacy reported in its original clinical trial.
However, the company said it still expects booster shots to be necessary ahead of the winter season as antibody levels are expected to wane.
It and Pfizer Inc and partner BioNTech SE, which make a similar messenger RNA-based vaccine, have been advocating for a third shot to maintain a high level of protection against Covid-19, especially as more contagious variants of the virus spread widely.
-Reuters -
